Skip to main content
Clinical Trials/NCT02091817
NCT02091817SuspendedEarly Phase 1

The Behavioral and Neural Effects of Oxytocin on Face Perception in Congenital Prosopagnosia

Soroka University Medical Center1 site in 1 country100 target enrollmentStarted: November 2013Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Early Phase 1
Status
Suspended
Enrollment
100
Locations
1
Primary Endpoint
Memory performance

Study Overview

Brief Summary

The purpose of this study is to determine whether oxytocin affect face perception

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Basic Science
Masking
Double (Participant, Investigator)

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • normal or corrected to normal vision

Exclusion Criteria

  • pregnancy (according to a pregnancy test taken by subjects prior to participation)
  • a history of asthma or nasal polyps
  • cardiac disorders
  • hyponatremia
  • acute or chronic renal insufficiency
  • liver cirrhosis
  • neurological disease
  • other chronic disease
  • dementia, or lack of judgment

Arms & Interventions

Control group

Other

Control group will be administered oxytocin and placebo, in a double-blind randomized order.

Intervention: Oxytocin (Drug)

Control group

Other

Control group will be administered oxytocin and placebo, in a double-blind randomized order.

Intervention: Placebo (Drug)

congenital prosopagnosia

Experimental

Congenital prosopagnosics will be administered oxytocin and placebo in a double-blind randomized order.

Intervention: Oxytocin (Drug)

congenital prosopagnosia

Experimental

Congenital prosopagnosics will be administered oxytocin and placebo in a double-blind randomized order.

Intervention: Placebo (Drug)

Outcomes

Primary Outcomes

Memory performance

Time Frame: Day 2 (24 hours after encoding)

At the day participants will administer the substance, they will view a set of faces, of which they will be tested about 24 hours later. The measures that will be tested are %accuracy and %dwell time of eye movements towards each region in the faces the participants saw.

Secondary Outcomes

  • Mood measurement(Day 1 (after oxytocin/placebo uptake))

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Ilan Shelef

Head of medical imaging at Soroka University Medical Center

Soroka University Medical Center

Study Sites (1)

Loading locations...

Similar Trials